Therapeutic lymphoma vaccines: importance of T-cell immunity

References

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood89(11), 3909–3918 (1997).
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Marcus RE. Follicular lymphoma: time for a re-think? Blood Rev.19(3), 165–178 (2005).
   PubMed Web of Science ®Google Scholar
• MacManus M, Hoppe R. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J. Clin. Oncol.14, 1282 (1996).
   PubMed Web of Science ®Google Scholar
• Chen M, Prosnitz L, Gonzalez-Serva A, Fisher D. Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma. Cancer43, 1245 (1979).
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood106(12), 3725–3732 (2005).
   PubMed Web of Science ®Google Scholar
• Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J. Clin. Oncol.23(33), 8447–8452 (2005).
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antobody and CHOP chemotherapy. J. Clin. Oncol.17, 268–276 (1999).
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol.22(23), 4711–4716 (2004). Erratum in: J. Clin. Oncol.23(1), 248 (2005).
   PubMed Web of Science ®Google Scholar
• Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N. Engl. J. Med.311(23), 1471–1475 (1984).
   PubMed Web of Science ®Google Scholar
• Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood97(1), 101–106 (2001).
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vukov AM, Habermann TM et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J. Clin. Oncol.23(6), 1103–1108 (2005).
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med.351(21), 2159–2169 (2004).
   PubMed Web of Science ®Google Scholar
• Sirisinha S, Eisen HN: Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc. Natl Acad. Sci. USA68, 3130–3135 (1971).
   PubMed Web of Science ®Google Scholar
• Lynch RG, Graff RJ, Sirisinha S et al. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl Acad. Sci. USA69, 1540–1544 (1972).
   PubMed Web of Science ®Google Scholar
• Stevenson GT, Stevenson FK: Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature254, 714–716 (1975).
   PubMed Web of Science ®Google Scholar
• Freedman PM, Autry JR, Tokuda S et al. Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. J. Natl Cancer Inst.56, 735–740 (1976).
   PubMed Web of Science ®Google Scholar
• Stevenson GT, Elliott EV, Stevenson FK. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Fed. Proc.36, 2268–2271 (1977).
   PubMedGoogle Scholar
• Kaminski MS, Kitamura K, Maloney DG et al. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J. Immunol.138, 1289–96 (1987).
   PubMed Web of Science ®Google Scholar
• Kwak LW, Campbell MJ, Zelenetz AD et al. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. Blood76, 2411–2417 (1990).
   PubMed Web of Science ®Google Scholar
• Kwak LW, Young HA, Pennington RW et al. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/ macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl Acad. Sci. USA93, 10972–10977 (1996).
   PubMed Web of Science ®Google Scholar
• Eager R, Nemunaitis J. GM-CSF gene-transduced tumor vaccines. Mol. Ther.12(1), 18–27 (2005)
   PubMed Web of Science ®Google Scholar
• Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med.327, 1209–1215 (1992).
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. Blood89, 3129–3135 (1997).
   Google Scholar
• Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med.5(10), 1171–1177 (1999).
   PubMed Web of Science ®Google Scholar
• Baskar S, Kobrin CB, Kwak LW. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J. Clin. Invest.113(10), 1498–1510 (2004).
   PubMed Web of Science ®Google Scholar
• Santos C, Stern L, Katz L, Watson T, Barry G. BiovaxIDTM vaccine therapy of follicular lymphoma in first remission: long-term follow-up of a Phase II trial and status of a controlled, randomized Phase III trial. Blood106, 2441 (2005).
   Google Scholar
• Longo DL, Duffey PL, Gribben JG et al. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a Phase II study. Cancer J.6(3), 146–150 (2000).
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood84, 2457–2466 (1994).
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol.16, 2825–2833 (1998).
   PubMed Web of Science ®Google Scholar
• Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B-cells inhibit induction of T-cell-dependent tumor immunity. Nat. Med.4, 627–630 (1998).
   PubMed Web of Science ®Google Scholar
• Steinman RM The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol.9, 271–296 (1991).
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Pinnas M, Wong T, Fitch FW. Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. J. Immunol.146, 1750–1758 (1991).
   PubMed Web of Science ®Google Scholar
• Eynon EE, Parker DC. Small B-cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J. Exp. Med.175, 131–8 (1992)
   PubMed Web of Science ®Google Scholar
• BennettSR, Carbone FR, Toy T, Miller JF, Heath WR. B-cells directly tolerize CD8(+) T-cells. J. Exp. Med.188, 1977–1983 (1998).
   PubMed Web of Science ®Google Scholar
• El-Amine M, Melo M, Kang Y, Nguyen H, Qian J, Scott DW. Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J. Immunol.165(10), 5631–5636 (2000).
   PubMed Web of Science ®Google Scholar
• Yang X, Brunham RC. Gene knockout B-cell-deficient mice demonstrate that B-cells play an important role in the initiation of T-cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. J. Immunol.161, 1439–1446 (1998).
   PubMed Web of Science ®Google Scholar
• Rivera A, Chen CC, Ron N, Dougherty JP, Ron Y. Role of B-cells as antigen-presenting cells in vivo revisited: antigen-specific B-cells are essential for T-cell expansion in lymph nodes and for systemic T-cell responses to low antigen concentrations. Int. Immunol.13, 1583–1593 (2001)
   PubMed Web of Science ®Google Scholar
• van Essen D, Dullforce P, Brocker T, Gray D. Cellular interactions involved in Th cell memory. J. Immunol.165, 3640–3646 (2000).
   PubMedGoogle Scholar
• Linton PJ, Harbertson J, Bradley LM. A critical role for B-cells in the development of memory CD4 cells. J. Immunol.165, 5558–5565 (2000).
   PubMedGoogle Scholar
• Shen H, Whitmire JK, Fan X, Shedlock DJ, Kaech SM, Ahmed R. A specific role for B-cells in the generation of CD8 T-cell memory by recombinant Listeria monocytogenes. J. Immunol.170, 1443–1451 (2003).
   PubMedGoogle Scholar
• Weisenburger DD, Armitage JO. Mantle cell lymphoma – an entity comes of age. Blood87(11), 4483–4494 (1996).
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann. Hematol.83(2), 71–77 (2004).
   Google Scholar
• Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J. Clin. Oncol.20(5), 1288–1294 (2002).
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J. Clin. Oncol.23(28), 7013–7023 (2005). Epub (2005).
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Kwak LW, Kobrin CB et al. Vaccine induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med.11(9), 986–991 (2005).
   PubMed Web of Science ®Google Scholar
• WengWK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol.22(23). 4717–24 (2004). (Epub). Erratum in: J. Clin. Oncol.23(1), 248(2005).
   PubMed Web of Science ®Google Scholar
• Koc O, Redfern C, Wiernik P et al. Extended follow-up and analysis with central radiological review of patients receiving FavId® (Id/KLH) vaccine following rituximab. Blood106, 772 (2005).
   Google Scholar
• Neelapu SS, Gause BL, Nikcevich DA et al. Phase III randomized trial of patient-specific vaccination for previously untreated follicular lymphoma patients in first complete remission: Protocol summary and interim report. Clin. Lymphoma6(1), 61–4 (2005).
   PubMedGoogle Scholar
• Vose JM. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. Hematol. Oncol.(2006) (Epub).
   PubMedGoogle Scholar
• Hurvitz SA, Timmerman JM. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin. Biol. Ther.5(6), 841–852 (2005).
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD, Levy R. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood97(5), 1370–1377 (2001).
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J. Immunol.164(9), 4797–4803 (2000).
   PubMed Web of Science ®Google Scholar
• Levitsky HI, Montgomery J, Ahmadzadeh M et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7–1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J. Immunol.156(10), 3858–3865 (1996).
   PubMed Web of Science ®Google Scholar
• KwakLW, Pennington R, Boni L, Ochoa AC, Robb RJ, Popescu MC. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J. Immunol.160(8), 3637–3684 (1998).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Weber J, Finke J et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother.25, 97–138 (2002).
   PubMed Web of Science ®Google Scholar
• Malyguine A, Strobl SL, Shafer-Weaver KA et al. A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J. Transl. Med.2(1), 9 (2004).
   PubMedGoogle Scholar
• Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med.2, 52–58 (1996).
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood99, 1517–1526, (2002).
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Baskar S, Gause BL et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin. Cancer Res.10(24), 8309–8317 (2004).
   PubMed Web of Science ®Google Scholar
• Nelson EL, Li X, Hsu FJ et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood88(2), 580–589 (1996).
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Kwak LW. Vaccine Approaches to non-hodgkin’s lymphoma therapy. In: Malignant Lymphomas, American Cancer Society Atlas of Clinical Oncology Series. Grossbard ML (Ed.), BC Decker, Inc., Hamilton, ON, Canada 316–329 (2002).
   Google Scholar
• Hawkins RE, Winter G, Hamblin TJ, Stevenson FK, Russell SJ. A genetic approach to idiotypic vaccination. J. Immunother.14(4), 273–278 (1993).
   Web of Science ®Google Scholar
• Hawkins RE, Zhu D, Ovecka M et al. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood83(11), 3279–3288 (1994).
   PubMed Web of Science ®Google Scholar
• Spellerberg MB, Zhu D, Thompsett A, King CA, Hamblin TJ, Stevenson FK. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J. Immunol.159(4), 1885–1892, (1997).
   PubMed Web of Science ®Google Scholar
• King CA, Spellerberg MB, Zhu D et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med.4(11), 1281–1286 (1998).
   PubMed Web of Science ®Google Scholar
• Biragyn T, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, t-cell dependent anti-tumor immunity. Nat. Biotech.17, 253–258 (1999).
   PubMed Web of Science ®Google Scholar
• Biragyn A, Surenhu M, Yang D et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol.167(11), 6644–6653 (2001).
   PubMed Web of Science ®Google Scholar
• Biragyn A, Ruffini PA, Coscia M et al. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood104(7), 1961–1969, (2004).
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Gause BL, Harvey L et al. Human autologous tumor-specific T-cell responses induced by liposome encapsulated lymphoma membrane proteins.(ASH Annual Meeting Abstracts) Blood104, 749 (2004).
   Google Scholar
• Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med.11(4 Suppl), S63–S68. Review (2005).
   PubMed Web of Science ®Google Scholar
• Shackleton M, Davis ID, Hopkins W et al. The impact of imiquimod, a toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun.4, 9 (2004).
   PubMedGoogle Scholar
• Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest.115(3), 739–746 (2005).
   PubMed Web of Science ®Google Scholar
• Walker LS, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol.2(1), 11–19 (2002).
   PubMed Web of Science ®Google Scholar
• Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol.4(5), 336–347 (2004).
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer5(4), 263–274. Review (2005).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol.6(4), 345–352 (2005).
   PubMed Web of Science ®Google Scholar
• Carter LL, Carreno BM. Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation. Immunol. Res.28(1), 49–59 (2003).
   PubMed Web of Science ®Google Scholar
• Sutmuller RP, van Duivenvoorde LM, van Elsas A et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med.194(6), 823–832 (2001).
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA99(19), 12293–12297 (2002).
   PubMed Web of Science ®Google Scholar
• Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol.17(2), 133–144 (2005).
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Wei S, Dong H et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med.9(5), 562–567 (2003).
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest.115(12), 3623–3633 (2005).
   PubMed Web of Science ®Google Scholar
• Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol.54(6), 369–377 (2005).
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA100(14), 8372–8377 (2003).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA100(8), 4712–4717 (2003).
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Singh G, Hermanson G et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res.62(20), 5845–5852 (2002).
   PubMed Web of Science ®Google Scholar
• Barrios Y, Cabrera R, Yanez R et al. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica87(4), 400–407 (2002).
   PubMed Web of Science ®Google Scholar